Login / Signup

Treatment of Behçet disease with oral roflumilast, an observational study.

Rodrigo Peñuelas-LealCarolina Labrandero HoyosJose Amancio Peñuelas RuizLeticia María Bagán DebónVioleta Zaragoza NinetJose Luis Sánchez CarazoGemma Pérez PastorAndrés Grau EchevarríaAltea Esteve MartínezMalena FinelloDaniel Blaya ImbernonVíctor Dios GuillánLucía Aguilar GonzálezJosé Vicente BagánVictor Alegre De Miquel
Published in: Clinical and experimental dermatology (2024)
Roflumilast appears a promising option in the treatment of Behçet's disease with favourable effectiveness, safety and tolerability profiles. Although further research is needed, roflumilast offers a promising treatment option for Behçet's Disease-associated aphthosis, which could improve patients' quality of life and address unmet therapeutic needs.
Keyphrases
  • end stage renal disease
  • randomized controlled trial
  • chronic kidney disease
  • ejection fraction
  • prognostic factors